Clinical Trial: Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07521046) titled 'Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)' on April 02.

Brief Summary: The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Myelofibrosis

Intervention: DRUG: ropeginterferon alfa- 2b

Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.

DRUG: Ruxolitinib

Ruxolitinib will be administered per standard of car...